We are Representative Office of Eisai (Thailand) Marketing Co., Ltd. Our corporate mission: We give first thought to patients and their families, and to increasing the benefits health care provides. We would like to find candidate contracting with Local Partners in charge of Eisai's business to work in Marketing field.
Knowledge Creation Recent hhc Activities Eisai's hhc Philosophy TOP Investors Management Policy IR Library IR Events Stock & Bond Information Eisai at a Glance Investors TOP Sustainability 28 countries 2. 01 billion tablets Number of countries supplied with lymphatic filariasis treatment and volume supplied (as of February 2021) Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries Sustainability Management Relationship with Customers Relationship with Society Relationship with Our Employees Relationship with Business Partners Environmental Activities Sustainability TOP Improving Access to Medicines TOP Initiatives for Lymphatic Filariasis Other Access to Medicines Initiatives Infectious Diseases Research & Development
Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here's a look. 6/13/2019 Eisai Inc. announced that it will present new data for FYCOMPA® (perampanel) CIII, including FREEDOM study results and the final results of one of the pediatric studies that supported the FDA approval for partial-onset seizures in patients as young as 4 years, at the upcoming 33rd International Epilepsy Congress (IEC) taking place on June 22-26, in Bangkok, Thailand. 6/11/2019 New analyses presented at SLEEP 2019 evaluated impact on key insomnia measures, including disease severity, sleep onset, sleep maintenance, and long-term safety, as well as next-day functioning Eisai Inc. today announced data on the respiratory safety of investigational lemborexant with multiple and single dosing in healthy adult and elderly individuals, as well as in those with mild obstructive sleep apnea (OSA). 6/4/2019 Targeting CXCR4 May Impact Aggressive Metastatic Behavior of Cancer Cells, Which May be Related to a Poor Prognosis Eisai Inc., the U. pharmaceutical subsidiary of Eisai Co., Ltd., announces the immediate appointment of Patrick Coyle as Vice President and Chief Financial Officer.
Lymphatic Filariasis Elimination Activities in Kenya Support for MDA and Provision of Water Tanks World NTD day World lights up to shine a light on the 1.
3 Months Versus 11.
Eisai (Thailand) Marketing Co., Ltd Location Unit 8. 6-8. 7, 8th Floor, Etown 3 - 364 Cong Hoa Street, Ward 13, Tan Binh District, Ho Chi Minh City Company Information Company size: 80 Field of operations: Limited Website: Jobs active $ Competitive Ha Noi | Hai Phong | Thanh Hoa About us We are Representative Office of Eisai (Thailand) Marketing Co., Ltd. Our corporate mission: We give first thought to patients and their families, and to increasing the benefits health care provides. We would like to find candidate contracting with Local Partners in charge of Eisai's business to work in Marketing field. Head Office: 6th Floor, 139 Pasteur, Ward 6, District 3, Ho Chi Minh City - Tel: (84. 28) 3822 6060 Hanoi Office: 17th Floor, VIT Tower, 519 Kim Ma Street, Ba Dinh District, Ha Noi - Tel: (84. 24) 7305 6060 Email: Copyright © CareerBuilder Vietnam.